吡贝地尔联合多巴丝肼治疗帕金森病疗效观察  

Effect of Piribedil Combined with Madopar in the Treatment of Parkinson's Disease

作　　者：彭潇[1] 黄慧芬[1] 

机构地区：[1]丽水市中心医院,浙江丽水323000

出　　处：《中国药师》2014年第5期806-807,共2页China Pharmacist

摘　　要：目的:观察吡贝地尔联合多巴丝肼治疗帕金森病的疗效和安全性。方法:58例帕金森病患者随机分为对照组和观察组,两组各29例,其中对照组单用多巴丝肼,观察组在对照组基础上加用吡贝地尔,连续治疗6个月后,采用帕金森病症状评分量表(UPDRS)进行疗效评定。结果:治疗6个月后观察组UPDRS运动评分较治疗前降低,降低程度优于对照组,两组治疗前后评分差值比较有统计学意义(P<0.05);观察组总有效率为89.7%,明显高于对照组的65.5%(P<0.05)。结论:吡贝地尔联合多巴丝肼治疗帕金森病较单用多巴丝肼疗效更佳,安全性好,值得临床推广应用。To observe the clinical effect of piribedil and madopar on Parkinsong disease （PD）. Methods： Totally 58 patients with PD were divided randomly into the treatment group （29 cases） and the control group （29 cases）. Piribedil and madopar were used in the treatment group, while only madopar was applied in the control group. Therapeutic effect of both groups was evaluated by UPDRS at the end of 6 courses. Results： The decrease of UPDRS after the remedy in the treatment group was more significant than that in the control group （P 〈0.05 ）, and the total effective rate in the treatment group（ 89.7% ） was significantly higher than that in the control group（65.5% ） （ P 〈 0.05 ）. Conclusion： The clinical effect of piribedil combined with madopar on PD is superior to that of madopar alone, therefore, the combination use is a useful method in the treatment of PD with the value of popularization and applica- tion：

关 键 词：帕金森病 吡贝地尔 多巴丝肼 

分 类 号：R971.5[医药卫生—药品]